Akari Therapeutics, Plc AKTX

$ 1.47 -6.37%

Quarterly report 2024-Q3
added 11-19-2024

Akari Therapeutics, Plc Balance Sheet 2011-2024 | AKTX

Annual Balance Sheet Akari Therapeutics, Plc

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-	-	-	-	-	-5.45 M	-28.1 M	-34.1 M	-68.9 M	-6.22 M	-7.66 M	-206 K	-6 K
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	50 K	60 K	50 K	268 K	787 K	630 K	276 K
Total Current Liabilities	24 M	20.5 M	10.8 M	-	-	-	-	-	11.7 M	21.1 M	1.36 M	1.23 M	3.85 M	-
Total Liabilities	24 M	20.8 M	15.6 M	6.09 M	5.22 M	8.57 M	4.92 M	11.9 M	11.8 M	21.2 M	1.63 M	2.02 M	4.48 M	2.51 M
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-42.7 M	-38.2 M	-25.3 M	-200 M	-182 M	-144 M	-127 M	-110 M	-74.9 M	-56.8 M	-30.2 M	-20.5 M	-16.9 M	-12.6 M
Total Assets	1.43 M	2.6 M	7.53 M	11.6 M	14.6 M	6.8 M	8.03 M	29 M	45.9 M	69.9 M	6.48 M	7.83 M	1.12 M	27 K
Cash and Cash Equivalents	-	3.84 M	13.2 M	-	14.1 M	5.73 M	5.45 M	28.1 M	34.1 M	68.9 M	3.33 M	554 K	1.1 M	6 K
Book Value	-22.6 M	-18.2 M	-8.09 M	5.55 M	9.38 M	-1.77 M	3.11 M	17.2 M	34.1 M	48.7 M	4.85 M	5.81 M	-3.36 M	-2.48 M
Total Shareholders Equity	-22.6 M	-18.2 M	-8.09 M	-1.94 M	9.38 M	7.6 K	3.11 M	17.2 M	34.1 M	48.7 M	2.22 M	401 K	-3.36 M	-2.48 M

All numbers in USD currency

Quarterly Balance Sheet Akari Therapeutics, Plc

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	213 K	-	48 K	-	58 K	-	56.4 K	-	55.1 K	52.1 K	49.1 K	46 K	1.03 M	49.1 K	-	-	268 K	268 K	787 K	-	-	-	630 K	-	-	-	276 K	-	-	-
Total Liabilities	-	-	-	-	-	-	-	-	-	-	-	6.09 M	-	3.24 M	-	5.22 M	6.75 M	8.49 M	6.41 M	6.47 M	5.37 M	4.15 M	3.39 M	4.92 M	-	8.49 M	-	11.9 M	-	9.2 M	-	11.8 M	-	17 M	16.6 M	21.2 M	37.8 M	-	21.2 M	1.17 M	1.17 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-243 M	-241 M	-233 M	-227 M	-	-	-	-	-	-	-	-200 M	-	-192 M	-	-182 M	-175 M	-176 M	-169 M	-165 M	-157 M	-154 M	-149 M	-127 M	-	-120 M	-	-110 M	-	-87.8 M	-	-74.9 M	-	-66.2 M	-59.8 M	-56.8 M	-63.3 M	-34.2 M	-56.8 M	-11.5 M	-11.5 M	-30.2 M	-30.2 M	-20.5 M	-	-	-	-16.9 M	-	-	-	-12.6 M	-	-	-
Total Assets	2.73 M	5.08 M	2.77 M	4.36 M	-	-	-	-	-	-	-	11.6 M	-	4.83 M	-	14.6 M	13.7 M	14.5 M	9.68 M	6.48 M	10.3 M	4.61 M	8.23 M	8.03 M	-	17.1 M	-	29.1 M	-	32.1 M	-	45.9 M	-	57.6 M	63 M	69.9 M	79.2 M	2.96 M	69.9 M	3.39 M	3.39 M	6.48 M	6.48 M	7.83 M	-	-	-	1.12 M	-	-	-	27 K	-	-	-
Cash and Cash Equivalents	2.25 M	4.18 M	1.31 M	3.84 M	4.73 M	7.18 M	11.6 M	-	-	-	-	9.36 M	-	3.79 M	-	14.1 M	12.3 M	12.7 M	7.82 M	5.73 M	6.27 M	2.74 M	6.15 M	5.45 M	-	15.1 M	-	28.1 M	-	30.1 M	-	34.1 M	-	9.66 M	61.4 M	68.9 M	78.8 M	201 K	68.9 M	3.33 M	3.33 M	6.22 M	6.22 M	554 K	-	-	-	1.1 M	-	-	-	6 K	-	-	-
Book Value	-	-	-	-	-	-	-	-	-	-	-	5.55 M	-	1.59 M	-	9.38 M	6.95 M	5.96 M	3.27 M	7.6 K	4.9 M	459 K	4.84 M	3.11 M	-	8.63 M	-	17.2 M	-	22.9 M	-	34.1 M	-	40.6 M	46.4 M	48.7 M	41.3 M	2.96 M	48.7 M	2.22 M	2.22 M	6.48 M	6.48 M	7.83 M	-	-	-	1.12 M	-	-	-	27 K	-	-	-
Total Shareholders Equity	-6.69 M	-3.7 M	-3.55 M	-229 K	213 K	2.78 M	6.56 M	-	-	-	-	5.55 M	-	1.59 M	3.94 M	9.38 M	6.95 M	5.96 M	3.27 M	7.6 K	4.9 M	459 K	4.84 M	4.37 M	-	8.63 M	16.3 M	22.2 M	-	22.9 M	-	34.1 M	-	40.6 M	46.4 M	48.7 M	41.3 M	973 K	48.7 M	2.22 M	2.22 M	4.85 M	4.85 M	401 K	-	-	-	-3.36 M	-	-	-	-2.48 M	-	-	-

All numbers in USD currency